Description
Known as a 5-hydroxytryptamine agonist, Rizatriptan Benzoate is the benzoate salt form of rizatriptan with anti-migraine activity, which can be used to treat the migraine headaches. It is FDA-approved to use in the treatment of acute migraine attacks with or without aura, especially taken at the first sign of a migraine headache. However, it cannot prevent future migraine attacks and it is ineffective to prevent other types of headache.
The pain of migraine headaches is believed to be induced by dilated blood vessels inside the head. Rizatriptan Benzoate relieves the pain by inducing vasoconstriction, which functions as an agonist at serotonin 5-HT1B and 5-HT1D receptors. The selective receptor binding is effective to constrict cranial vessels and inhibit the transmission of nociception, thus providing relief of migraine headaches.
References
https://en.wikipedia.org/wiki/Rizatriptan
https://pubchem.ncbi.nlm.nih.gov/compound/77997#section=Top
http://bodyandhealth.canada.com/drug/getdrug/co-rizatriptan-odt
Description
Rizatriptan was launched for the first time as Maxalt in Mexico for the
acute treatment of migraine headaches with or without aura in adults. It is the
third in a new generation of triptan migraine drugs to challenge the firstgeneration
product Sumatriptan from Glaxo Wellcome, after Zolmitriptan
(Zeneca) and Naratriptan (Glaxo Wellcome).
It can be synthetically obtained by two related routes having respectively 3 and 4
steps, both starting from 1 -(4-aminobenzyl)-l,2,4-triazole. Rizatriptan is a full 5-HT1D/1B receptor agonist retaining a significant affinity at 5-HT1A sites (pIC50
= 6.4), with a low affinity for nond-HT sites. It shows craniovascufar selectivity
for human isolated middle meningeal over coronary arteries ; its effect on
coronary artery constriction is significantly less than that for Sumatriptan.
Rizatriptan inhibits the release of neuropeptides that cause swelling of cranial
blood vessels. Rizatriptan has a good oral bioavailability (64% and 47% in rats
and dogs respectively). and a rapid onset of action : the headache relief in
human occurs within 30 to 45 minutes of taking 20 mg. It also relieved nausea
and hypersensitivity to noise (phonophobia) and light (photophobia) that are
often symptoms accompanying a migraine attack. Among at least 6 metabolites
identified in humans after a single oral dose (60 mg), the major urinary
metabolite was the corresponding indole-3-acetic acid. Maxalt is available as a
novel oral formulation of rapidly dissolving tablets or wafers that does not require
liquid for ingestion.
Chemical Properties
Off-White Solid
Originator
Merck & Co (US)
Uses
Rizatriptan Benzoate(Maxalt) is a 5-HT1 agonist triptan drug for the treatment of migraine headaches. It is believed to work by narrowing the blood vessels around the brain. Rizatriptan also reduces the substances in the body, which can also reduce headac
Uses
A selective serotonin 5-HTID receptor agonist. Structurally derived from tryptamine
Uses
Rizatriptan Benzoate is a selective serotonin 5-HTID receptor agonist and used to treat migraine (1,2,3). It is structurally derived from tryptamine.
Definition
ChEBI: Rizatriptan benzoate is a member of tryptamines.
brand name
Maxalt (Merck).
General Description
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
Biochem/physiol Actions
Rizatriptan is a serotonin 5HT-1B/1D-receptor agonist used to treat migraine.
Synthesis
A method for the preparation of rizatriptan benzoate, characterized in that it is carried out in the following steps: using 4-chlorobutanal as a raw material, and reacting with sodium metabisulfite in an addition reaction to obtain sodium 4-chlorobutane-1,1-disulfonate; reacting sodium 4-chlorobutane-1,1-disulfonate with 1-(4-hydrazinylphenyl)methyl-1,2,4-triazole hydrochloride in a mixed solution of alcohol-water in the presence of a catalyst After that, 3-(2-chloroethyl)-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole was obtained by alkali neutralization and concentration by solvent extraction; (iii) 3-(2-chloroethyl)-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole was reacted with dimethylamine, and rizatriptan was obtained by the action of a phase-transferring catalyst; (iv) Rizatriptan and benzoic acid were salted in a solvent to form a salt of rizatriptan benzoate, and then refined with ethanol to obtain rizatriptan benzoate boutique.
